Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | MicrobiomeTrials
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2021-08-09Est. Completion: 2027-03-31
Enrollment target: 51 participants
Locations
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
Los Angeles General Medical Center, Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
UF Health Cancer Institute - Gainesville, Gainesville, Florida, United States
Memorial Hospital East, Shiloh, Illinois, United States
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri, United States
Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
Washington University School of Medicine, St Louis, Missouri, United States
Siteman Cancer Center-South County, St Louis, Missouri, United States
Siteman Cancer Center at Christian Hospital, St Louis, Missouri, United States
NYP/Weill Cornell Medical Center, New York, New York, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
University of Texas at Austin, Austin, Texas, United States
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
University of Texas Medical Branch, Galveston, Texas, United States
UT MD Anderson Cancer Center, Houston, Texas, United States
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Other microbiome trials you might be interested in
Breast CancerSmall Cell Lung CancerOvarian CancerGastric CancerHormone-receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerAdvanced Solid TumorEndometrial CancerProstate CancerTNBC - Triple-Negative Breast CancerGastroEsophageal CancerBladder Cancer
This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to a…
Newport Beach, United StatesEst. completion Aug 31, 2026